The government may decide on allowing Serum Institute of India’s (SII) Covovax as a heterologous booster dose, meaning it can be used for people who have taken either Covishield or Covaxin for primary vaccination against Covid-19...
In 2023, it is expected that the shift towards personalised medicine will continue as more and more pharmaceutical companies concentrate on creating medications that are customised for specific individuals.
Sirio Pharma Co., Ltd. (Sirio), a leading global CDMO, has announced the completion of its acquisition of a majority stake in Best Formulations LLC, a California-based contract manufacturer of nutritional supplements and personal care products...
COVAXIN (BBV152; Clinicaltrials.gov, NCT05258669), a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades,...
AstraZeneca announced that it will spend around $1.8 billion to acquire the clinical-stage biopharmaceutical company CinCor Pharma Inc., based in the United States, in order to expand its line of heart and kidney medications...
IntoCell, a South Korean biotech that is developing novel antibody drug conjugate (ADC) platform technologies, will provide proprietary drug-linkers developed using their proprietary Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) system and payload...
The Indian pharmaceutical industry was ripe for disruption, & the exigencies built by the covid-19 pandemic provided the e-pharmacy format the highly required push
BioNTech SE announced a partnership with the UK government to enrol up to 10,000 patients in clinical trials for personalised cancer therapies by the end of 2030...
Gobal pharma major Lupin Limited has announced the launch of a novel fixed-dose triple drug combination (FDC) of Indacaterol, Glycopyrronium and Mometasone, under the brand name DIFIZMA in India, for managing inadequately controlled asthma among...
Aurobindo Pharma on said its wholly-owned subsidiary Eugia Pharma Specialities received final approval from the US Food and Drug Administration (US FDA) to manufacture and market Azacitidine for injection 100 mg single-dose vial....
, CDSCO.jpg)
